Hutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases’ treatment developer - Starts phase one study in China of its SHP2 inhibitor HMPL-415 for the treatment of advanced malignant solid tumours. First patient received their first dose on Thursday last week. Hutchmed expects up to 80 patients to take part in the study. SHP2 is a non-receptor protein tyrosine phosphatase which controls cell growth and cell migration.

Current stock price: 193.00 pence

12-month change: down 22%

Copyright 2023 Alliance News Ltd. All Rights Reserved.